Lead Candidate NU-3 Shows Strong Antimicrobial Resistance Data for Diabetic Foot Ulcers
LABT sits 63% above its 52-week low of $2.58 on elevated volume (5.6× avg).
Summary
Lakewood-Amedex Biotherapeutics announced positive antimicrobial resistance data for NU-3, its lead candidate targeting infected diabetic foot ulcers. Laboratory studies demonstrated that NU-3 developed low resistance compared to ciprofloxacin and maintained activity against ciprofloxacin-resistant bacteria. This is a significant positive development for the company's pipeline, as a strong resistance profile is crucial for the long-term efficacy and market potential of antimicrobial drugs, particularly for challenging infections like diabetic foot ulcers. For a micro-cap biotech, this data provides important validation for its lead asset and could significantly de-risk its development pathway. Investors will now watch for further clinical trial progression and regulatory updates.
At the time of this announcement, LABT was trading at $4.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.1M. The 52-week trading range was $2.58 to $9.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.